Phage therapy: Unexpected drawbacks to reach hospitals

The use of phages to kill pathogenic bacteria is an old practice to cure infectious diseases. The current antibiotic crisis has boosted phage therapy research, but its application in hospitals is still very limited. Here, we analyze the problems that need to be solved to go forward with this renewed...

Descripción completa

Detalles Bibliográficos
Autores: Álvarez, Andrea, Fernández Llamas, Lucía, Iglesias, Beatriz, Rodríguez-Carrio, Javier, García Suárez, María Pilar
Tipo de recurso: artículo
Estado:Versión aceptada para publicación
Fecha de publicación:2020
País:España
Institución:Consejo Superior de Investigaciones Científicas (CSIC)
Repositorio:DIGITAL.CSIC. Repositorio Institucional del CSIC
OAI Identifier:oai:digital.csic.es:10261/223114
Acceso en línea:http://hdl.handle.net/10261/223114
Access Level:acceso abierto
Palabra clave:Antibiotic resistance
Hospitals
Infectious diseases
New antibiotics
Phage therapy
id ES_99edad0106a6a5bbdfee85dde11eb3b0
oai_identifier_str oai:digital.csic.es:10261/223114
network_acronym_str ES
network_name_str España
repository_id_str
spelling Phage therapy: Unexpected drawbacks to reach hospitalsÁlvarez, AndreaFernández Llamas, LucíaIglesias, BeatrizRodríguez-Carrio, JavierGarcía Suárez, María PilarAntibiotic resistanceHospitalsInfectious diseasesNew antibioticsPhage therapyThe use of phages to kill pathogenic bacteria is an old practice to cure infectious diseases. The current antibiotic crisis has boosted phage therapy research, but its application in hospitals is still very limited. Here, we analyze the problems that need to be solved to go forward with this renewed therapy, hoping that it can be useful for patients suffering from an incurable infection. We would like to emphasize that phage therapy is right now at a crossroads. This may be similar to what happened a century ago with the arrival of antibiotics, but now we do not have such a good alternative. Therefore, let us not waste this opportunity, even if a radical change in our health strategy is necessary.This study was funded by grants AGL2015-65673-R (MINECO/FEDER/EU, Spain), EU ANIWHA ERA-NET (BLAAT ID: 67)/PCIN2017-001 (AEI/FEDER/EU, Spain), Proyecto Intramural CSIC 201770E016, IDI/2018/000119 (Asturias Innovation 2018–2020, Principado de Asturias, Spain) and FEDER/EU. P Garcia and A Rodrıguez are members of the bacteriophage network FAGOMA and the FWO Vlaanderen funded ‘Phagebiotics’ research community (WO.016.14)Peer reviewedFuture MedicineMinisterio de Economía y Competitividad (España)European CommissionPrincipado de AsturiasFernández, Lucía [0000-0002-7383-7595]García Suárez, María Pilar [0000-0003-1213-8165]Consejo Superior de Investigaciones Científicas [https://ror.org/02gfc7t72]202020202020info:eu-repo/semantics/articlehttp://purl.org/coar/resource_type/c_6501Postprintinfo:eu-repo/semantics/acceptedVersionhttp://hdl.handle.net/10261/223114reponame:DIGITAL.CSIC. Repositorio Institucional del CSICinstname:Consejo Superior de Investigaciones Científicas (CSIC)Inglés#PLACEHOLDER_PARENT_METADATA_VALUE#info:eu-repo/grantAgreement/MINECO/Plan Estatal de Investigación Científica y Técnica y de Innovación 2013-2016/AGL2015-65673-Rhttp://dx.doi.org/10.2217/fvl-2019-0154Síinfo:eu-repo/semantics/openAccessoai:digital.csic.es:10261/2231142026-05-22T06:33:51Z
dc.title.none.fl_str_mv Phage therapy: Unexpected drawbacks to reach hospitals
title Phage therapy: Unexpected drawbacks to reach hospitals
spellingShingle Phage therapy: Unexpected drawbacks to reach hospitals
Álvarez, Andrea
Antibiotic resistance
Hospitals
Infectious diseases
New antibiotics
Phage therapy
title_short Phage therapy: Unexpected drawbacks to reach hospitals
title_full Phage therapy: Unexpected drawbacks to reach hospitals
title_fullStr Phage therapy: Unexpected drawbacks to reach hospitals
title_full_unstemmed Phage therapy: Unexpected drawbacks to reach hospitals
title_sort Phage therapy: Unexpected drawbacks to reach hospitals
dc.creator.none.fl_str_mv Álvarez, Andrea
Fernández Llamas, Lucía
Iglesias, Beatriz
Rodríguez-Carrio, Javier
García Suárez, María Pilar
author Álvarez, Andrea
author_facet Álvarez, Andrea
Fernández Llamas, Lucía
Iglesias, Beatriz
Rodríguez-Carrio, Javier
García Suárez, María Pilar
author_role author
author2 Fernández Llamas, Lucía
Iglesias, Beatriz
Rodríguez-Carrio, Javier
García Suárez, María Pilar
author2_role author
author
author
author
dc.contributor.none.fl_str_mv Ministerio de Economía y Competitividad (España)
European Commission
Principado de Asturias
Fernández, Lucía [0000-0002-7383-7595]
García Suárez, María Pilar [0000-0003-1213-8165]
Consejo Superior de Investigaciones Científicas [https://ror.org/02gfc7t72]
dc.subject.none.fl_str_mv Antibiotic resistance
Hospitals
Infectious diseases
New antibiotics
Phage therapy
topic Antibiotic resistance
Hospitals
Infectious diseases
New antibiotics
Phage therapy
description The use of phages to kill pathogenic bacteria is an old practice to cure infectious diseases. The current antibiotic crisis has boosted phage therapy research, but its application in hospitals is still very limited. Here, we analyze the problems that need to be solved to go forward with this renewed therapy, hoping that it can be useful for patients suffering from an incurable infection. We would like to emphasize that phage therapy is right now at a crossroads. This may be similar to what happened a century ago with the arrival of antibiotics, but now we do not have such a good alternative. Therefore, let us not waste this opportunity, even if a radical change in our health strategy is necessary.
publishDate 2020
dc.date.none.fl_str_mv 2020
2020
2020
dc.type.none.fl_str_mv info:eu-repo/semantics/article
http://purl.org/coar/resource_type/c_6501
Postprint
info:eu-repo/semantics/acceptedVersion
format article
status_str acceptedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/10261/223114
url http://hdl.handle.net/10261/223114
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.relation.none.fl_str_mv #PLACEHOLDER_PARENT_METADATA_VALUE#
info:eu-repo/grantAgreement/MINECO/Plan Estatal de Investigación Científica y Técnica y de Innovación 2013-2016/AGL2015-65673-R
http://dx.doi.org/10.2217/fvl-2019-0154
Sí
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.publisher.none.fl_str_mv Future Medicine
publisher.none.fl_str_mv Future Medicine
dc.source.none.fl_str_mv reponame:DIGITAL.CSIC. Repositorio Institucional del CSIC
instname:Consejo Superior de Investigaciones Científicas (CSIC)
instname_str Consejo Superior de Investigaciones Científicas (CSIC)
reponame_str DIGITAL.CSIC. Repositorio Institucional del CSIC
collection DIGITAL.CSIC. Repositorio Institucional del CSIC
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869414329595461632
score 15.812455

Similares en LA Referencia